Literature DB >> 20524820

Which psychosocial factors are related to chelation adherence in thalassemia? A systematic review.

Michael Evangeli1, Kulsoom Mughal, John B Porter.   

Abstract

Good adherence to iron chelation therapy in thalassemia is crucial. Although there is evidence that adherence is related to regimen factors, there has been less emphasis on the relationship between psychosocial (psychological, demographic and social) factors and adherence. We present a systematic review of psychosocial correlates of chelation adherence in thalassemia. Nine studies met the inclusion criteria. Information was extracted regarding the study characteristics and the relationship between psychosocial factors and chelation adherence. Methodological quality was rated. The studies took place in a range of countries, were mostly cross sectional in design, and examined adherence to deferoxamine (DFO) only. Sample sizes ranged from 15 to 1573. A variety of psychosocial variables were examined. Definitions of adherence varied between studies and non adherence rates were also variable (9 to 66%). Older age was consistently associated with lower levels of chelation adherence. There were few other consistent findings. The methodological quality of studies was variable. There is a need for more methodologically sophisticated and theoretically informed studies on psychosocial correlates of chelation adherence. We offer specific suggestions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20524820     DOI: 10.3109/03630269.2010.485080

Source DB:  PubMed          Journal:  Hemoglobin        ISSN: 0363-0269            Impact factor:   0.849


  12 in total

1.  Challenges of adherence and persistence with iron chelation therapy.

Authors:  John B Porter; Michael Evangeli; Amal El-Beshlawy
Journal:  Int J Hematol       Date:  2011-10-13       Impact factor: 2.490

2.  Computer and mobile technology interventions to promote medication adherence and disease management in people with thalassemia.

Authors:  Sherif M Badawy; Kerry Morrone; Alexis Thompson; Tonya M Palermo
Journal:  Cochrane Database Syst Rev       Date:  2019-06-28

3.  Iron chelation adherence to deferoxamine and deferasirox in thalassemia.

Authors:  Felicia Trachtenberg; Elliott Vichinsky; Dru Haines; Zahra Pakbaz; Lauren Mednick; Amy Sobota; Janet Kwiatkowski; Alexis A Thompson; John Porter; Thomas Coates; Patricia J Giardina; Nancy Olivieri; Robert Yamashita; Ellis J Neufeld
Journal:  Am J Hematol       Date:  2011-05       Impact factor: 10.047

4.  Concordance with comprehensive iron assessment, hepatitis A vaccination, and hepatitis B vaccination recommendations among patients with sickle cell disease and thalassaemia receiving chronic transfusions: an analysis from the Centers for Disease Control haemoglobinopathy blood safety project.

Authors:  Sherif M Badawy; Amanda B Payne; Mary M Hulihan; Thomas D Coates; Suvankar Majumdar; Dominic Smith; Alexis A Thompson
Journal:  Br J Haematol       Date:  2021-08-24       Impact factor: 8.615

5.  Psychometric properties of the Specific Thalassemia Quality of Life Instrument for adults.

Authors:  Georgios N Lyrakos; Demetra Vini; Helen Aslani; Marouso Drosou-Servou
Journal:  Patient Prefer Adherence       Date:  2012-07-02       Impact factor: 2.711

6.  Negative affect differentiation and adherence during treatment for thalassemia.

Authors:  Karin G Coifman; Gail S Ross; Dorothy Kleinert; Patricia Giardina
Journal:  Int J Behav Med       Date:  2014-02

7.  Computer and mobile technology interventions to promote medication adherence and disease management in people with thalassemia.

Authors:  Sherif M Badawy; Kerry Morrone; Alexis Thompson; Tonya M Palermo
Journal:  Cochrane Database Syst Rev       Date:  2017-12-14

8.  Patient Perspective on Iron Chelation Therapy: Barriers and Facilitators of Medication Adherence.

Authors:  Chia Chee Chong; Adyani Md Redzuan; Jameela Sathar; Mohd Makmor-Bakry
Journal:  J Patient Exp       Date:  2021-03-03

9.  Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial.

Authors:  John Porter; Donald K Bowden; Marina Economou; Jacques Troncy; Arnold Ganser; Dany Habr; Nicolas Martin; Adam Gater; Diana Rofail; Linda Abetz-Webb; Helen Lau; Maria Domenica Cappellini
Journal:  Anemia       Date:  2012-08-12

Review 10.  Regional consensus opinion for the management of Beta thalassemia major in the Arabian Gulf area.

Authors:  Mohamad H Qari; Yasser Wali; Muneer H Albagshi; Mohammad Alshahrani; Azzah Alzahrani; Ibrahim A Alhijji; Abdulkareem Almomen; Abdullah Aljefri; Hussain H Al Saeed; Shaker Abdullah; Ahmad Al Rustumani; Khoutir Mahour; Shaker A Mousa
Journal:  Orphanet J Rare Dis       Date:  2013-09-17       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.